This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company’s growth drivers, including new product sales in Australia and Europe, and outlines their strategy to maintain market share and expand in emerging European markets.
More From The Market Online
BPM Minerals granted Bonnie and Clyde drilling approvals
BPM Minerals has received the final key approval allowing for the maiden Bonnie & Clyde drilling…
- Colin Sandell-Hay
- 2 mins
- 11 September 2026 10:24 (AEST)
Emperor signs contract rig for critical Judith-2 gas appraisal well
Emperor Energy is aiming to drill an appraisal well on Judith, the largest undeveloped conventional gas…
- Colin Sandell-Hay
- 3 mins
- 08 September 2026 16:01 (AEST)
Omega Oil & Gas kicks off key new Taroom Trough well at Canyon-4
Omega Oil & Gas has kicked off the next key well aimed at confirming the world-class…
- Colin Sandell-Hay
- 2 mins
- 07 September 2026 16:06 (AEST)
Market Open: Oil shock puts inflation and rates back in focus
Brent crude has surged above US$107 a barrel as escalating Middle East tensions raise fresh concerns…
- Colin Sandell-Hay
- 3 mins
- 11 September 2026 09:01 (AEST)
